<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00929851</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0906-PR-0016</org_study_id>
    <secondary_id>2009-012546-23</secondary_id>
    <nct_id>NCT00929851</nct_id>
  </id_info>
  <brief_title>BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)</brief_title>
  <official_title>a 48-week, Double Blind, Randomized, Multinational, Multicentre, &quot;Fixed Combination&quot; Beclomethasone Dipropionate Plus Formoterol Fumarate Versus Formoterol in Patients With Severe Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      a 48-week, 2-arm parallel group, &quot;fixed combination&quot; beclomethasone dipropionate plus
      formoterol fumarate versus formoterol in patients with severe chronic obstructive pulmonary
      disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      a 48-week, double blind, randomized, multinational, multicentre, 2-arm parallel group,
      reference treatment controlled clinical trial of &quot;fixed combination&quot; beclomethasone
      dipropionate plus formoterol fumarate versus formoterol in patients with severe chronic
      obstructive pulmonary disease
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exacerbation rate Change in pre-dose FEV1</measure>
    <time_frame>0-4-12-24-36-48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function parameters(FEV1 - FVC) St George's Questionnaire Use of rescue medication</measure>
    <time_frame>0-4-12-24-36-48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1199</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>BDP/FF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol fumarate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol fumarate 12 µg per metered dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF1535</intervention_name>
    <description>Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose</description>
    <arm_group_label>BDP/FF</arm_group_label>
    <other_name>Foster, Fostair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol fumarate</intervention_name>
    <description>Formoterol fumarate 12 µg per metered dose</description>
    <arm_group_label>Formoterol fumarate</arm_group_label>
    <other_name>Atimos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe COPD

          -  At least one COPd exacerbation in previous year

        Exclusion Criteria:

          -  Asthma, allergic rhinitis or other atopic disease

          -  Unstable concurrent disease:

          -  Evidence of heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jadwiga A Wedzicha, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL MEDICAL SCHOOL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCL Medical School</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012546-23</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <results_reference>
    <citation>Wedzicha JA, Singh D, Vestbo J, Paggiaro PL, Jones PW, Bonnet-Gonod F, Cohuet G, Corradi M, Vezzoli S, Petruzzelli S, Agusti A; FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014 Aug;108(8):1153-62. doi: 10.1016/j.rmed.2014.05.013. Epub 2014 Jun 6. Erratum in: Respir Med. 2015 Mar;109(3):434-5.</citation>
    <PMID>24953015</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

